Mannatech, Inc. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014, compared with 2013. This annual filing does not provide standalone fourth-quarter results in the supplied text.
Business context
Mannatech develops and sells nutritional supplements, skin-care and anti-aging products, and weight-management products through independent associates and members in 24 countries. The company reports one operating segment and had approximately 230,000 active associates and members who purchased products in the prior 12 months, down from approximately 245,000 in 2013.
Financial performance and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Net sales | $190.1 million | $177.4 million |
| Gross profit / margin | $151.7 million / 79.8% | $141.3 million / 79.7% |
| Operating income / margin | $12.7 million / 6.7% | $4.8 million / 2.7% |
| Net income | $6.5 million | $3.2 million |
| Diluted EPS | $2.40 | $1.18 |
| Cash provided by operations | $9.4 million | $8.5 million |
| Cash and cash equivalents at year-end | $28.0 million | $20.4 million |
| Working capital at year-end | $16.4 million | $13.7 million |
Gross margin was essentially stable. Operating expenses were $139.0 million, versus $136.6 million; commissions and incentives totaled $75.2 million, or 39.6% of sales, compared with $75.6 million, or 42.6%. Other expense, net, rose to $3.0 million, primarily reflecting foreign-exchange losses. The effective tax rate was 33.9%, versus a 13.0% tax benefit rate in 2013.
Cash from investing activities was a $1.5 million outflow and financing activities used $1.4 million, mainly for capital-lease repayments. Year-end restricted cash was $8.6 million. Capital-lease obligations had a $1.8 million present value; the filing states that the company generally funds operations from operating cash flow rather than long-term debt. Management said available liquidity and operating cash flows should fund normal operations for the next 12 months, subject to sales and cost performance.
Material changes versus 2013
- Reported sales increased 7.1%; on a constant-currency basis, management reported growth of 7.9%. Foreign exchange reduced reported sales by $1.4 million.
- Growth was concentrated in Asia/Pacific, where sales rose 15.1% to $92.4 million, and EMEA, up 13.4% to $16.9 million. North America sales fell 1.7% to $80.8 million.
- Management attributed much of the year-over-year sales comparison to the expansion of the üth skin-care product and the loyalty program. Excluding those effects, management said sales would have increased just $0.1 million.
- New-associate and member pack sales increased 89.1% to $19.1 million, while continuing-associate pack sales fell 46.0% to $8.7 million. Total active purchasers declined by approximately 15,000.
- The four largest disclosed product lines—Advanced Ambrotose, Ambrotose, üth Skin Rejuvenation, and NutriVerus—accounted for 51.9% of sales, up from 47.5% in 2013.
- Deferred revenue rose to $10.9 million from $6.4 million, including $9.7 million related to loyalty points, as the program was modified to allow faster vesting.
Outlook, risks, contingencies, and unusual items
- The company planned to begin operations in Colombia by the end of the third quarter of 2015. No specific revenue, earnings, or margin guidance is provided.
- Key risks include retaining and recruiting associates, dependence on a small group of important products, intense competition, product-claim and network-marketing regulation, and the conduct of independent associates. Currency exposure is significant: 66.8% of 2014 sales were outside the United States, and the company did not hedge foreign-exchange risk.
- All products are made by third parties. The filing identifies no alternative supplier for Arabinogalactan, an ingredient used in Ambrotose, creating a potential supply-continuity risk.
- A patent infringement case remained open; the court denied Mannatech’s preliminary-injunction motion. A separate breach-of-contract suit filed in February 2015 sought more than $1 million; the company said the potential liability could not yet be estimated and intended to defend the claim. A former executive’s employment case was settled and dismissed in 2014.
- The company disclosed ongoing tax audits and disputes and said adverse outcomes could affect cash. Its deferred-tax valuation allowance increased to $9.7 million from $5.3 million. A prior IRS audit settlement contributed to the 2013 tax benefit, complicating year-over-year earnings comparisons.
- The founder’s consulting agreement expired without renewal in February 2014; the founder subsequently launched a competing business. The filing identifies possible disputes as a business risk.
- Dividends were not paid; the board suspended them in 2009. Management reported effective disclosure controls and internal control over financial reporting. The independent auditor issued an unqualified opinion on the financial statements.
Most important facts for investors to verify
- Whether sales growth continues after accounting for the üth launch, loyalty-point revenue timing, and foreign-exchange effects.
- Whether the shrinking active purchaser base stabilizes and whether new recruitment translates into repeat product orders.
- How loyalty-point redemptions, forfeitures, and deferred revenue affect future reported revenue and commissions.
- Progress and potential financial exposure in the patent and contract litigation, tax audits, and other regulatory matters.
- Whether the company can sustain operating cash flow and liquidity while meeting lease, purchase, and other contractual commitments.
- Whether product concentration and dependence on third-party suppliers, particularly for Arabinogalactan, create material sales or margin exposure.